Sunday, May 11

Biogen Idec And Elan Enroll First Patient In Large, Well-Controlled Head-to-Head Study Of Multiple Sclerosis Treatments

( Posted by- Desinie Smith )

Biogen Idec (NASDAQ: BIIB) andElan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis (RRMS). The study, called SURPASS, is expected to enroll 1,800 patients in 27 countries and provide direct comparative data of different treatment options for RRMS patients who experience breakthrough disease activity.